Bispecific antibody · Immune activation, directed at CD19, CD3 (CD3E) and CD2 · developed by Novartis Pharmaceuticals
PIT565 is an antibody that binds CD19 on tumor cells and CD3 and CD2 on T-cells, cross-linking them to trigger a cytotoxic T-lymphocyte response against CD19-expressing cells. It is being studied in B-cell non-Hodgkin lymphoma and B-cell acute lymphoblastic leukemia.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05397496 | Phase 1 | B-cell Non-Hodgkin Lymphoma (B-NHL) | Active not recruiting | NVS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
B-cell Acute Lymphoblastic Leukemia (B-ALL)B-cell Non-Hodgkin Lymphoma (B-NHL)
Updated Nov 22, 2026. Something wrong or missing? Report it on the NVS page.
See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NVS catalysts and pipeline →